Serina Therapeutics Inc (SER) — Titan Protect Analysis

SER

Serina Therapeutics Inc

Healthcare · ·

$1.88

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$26M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-1.66

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-221.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$11.00

+485% from current price — median analyst estimate

Recommendation

NONE

Consensus view from 1 analysts covering this stock

About Serina Therapeutics Inc

Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252 (POZ-apomorphine), a POZ conjugate for the treatment of advanced Parkinson's disease that is in phase 1 clinical trial; and POZ-lipids, a non-immunogenic alternative to the PEG-lipids in the lipid nanoparticles. The company also develops SER 214, a POZ conjugate of rotigotine for the treatment of early Parkinson's and Restless Leg Syndrome, which has c

https://serinatherapeutics.com

Country: United States Employees: 16 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.114

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0390

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.611

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-55.0%

Historical annualised return based on price data

Max Drawdown

-90.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$7.92

76% below the year high

52W Low

$1.22

54% above the year low

Avg Volume

3,235,398

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.2

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-2.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

17.98

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

-18,803.1%

Profit from core operations before interest and tax

Free Cash Flow

$-7,911,750

Negative — the business is spending more than it generates

Revenue (TTM)

$130,000

Total revenue over the last 12 months

Net Income

$-21,521,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$11.00

Target Median

$11.00

Target Low

$11.00

Political Trading Activity

Congressional trading disclosures involving this instrument

Date	Politician	Party	Type	Amount
24 Apr2026	Josh Gottheimer	Democrat	sell	1K–15K
2026-05-07	Dwight Evans	Democrat	Sale	1K–15K
2026-04-24	Josh Gottheimer	Democrat	Sale	1K–15K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K
2026-04-13	Ro Khanna	Democrat	Purchase	1K–15K

Source: Congressional disclosure filings. View all political trades at

Insider Intelligence

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go